Table 3.
Summary estimates of the OR for the associations of BCL-6 rearrangement and clinical-pathological features of DLBCL.
| Clinicopathological features | Number of studies | Number of patients | Pooled OR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 | P value | |||||
| Age (<60 vs. ≥60) | 5 | 485 | 0.943 (0.771-1.153) | 0.566 | 0.00% | 0.595 |
| Gender (Female vs. Male) | 8 | 838 | 0.897 (0.746-1.079) | 0.248 | 0.00% | 0.631 |
| Tumor stage (I-II vs. III-IV) | 10 | 1083 | 0.916 (0.773-1.086) | 0.313 | 0.00% | 0.744 |
| Type (GCB vs. ABC) | 6 | 1337 | 0.454 (0.292-0.704) | 0.000 | 51.70% | 0.066 |
| IPI score (3-5 vs.0-2) | 6 | 696 | 1.215 (1.031-1.433) | 0.042 | 15.40% | 0.315 |
| Primary site (Nodal vs. Extranodal) | 4 | 570 | 1.006 (0.863-1.174) | 0.935 | 64.00% | 0.039 |
| Extranodal site (No vs. Yes) | 5 | 445 | 1.012 (0.891-1.150) | 0.851 | 1.90% | 0.396 |
| BCL2 expression (+ vs. -) | 4 | 463 | 1.071 (0.901-1.272) | 0.437 | 60.70% | 0.054 |
| BCL6 expression (+ vs. -) | 3 | 452 | 1.015 (0.875-1.179) | 0.841 | 63.50% | 0.065 |
| Serous LDH (Elevated vs. Normal) | 8 | 739 | 2.188 (1.667-2.874) | 0.000 | 74.30% | 0.000 |
| Bone marrow involvement (+ vs. -) | 4 | 436 | 0.795 (0.542-1.168) | 0.243 | 0.00% | 0.565 |
Abbreviations: DLBCL, diffuse large B-cell lymphoms; OR, odd ratio; 95% CI, 95% confidence interval; GBC, germinal center B-cell-like; ABC, activated B-cell-like.